Forma Therapeutics, Inc.

Novo Nordisk Healthcare Ag

Valo Health, Inc.

Cara Therapeutics, Inc.

Bayer Pharmaceuticals Corporation

Valo Early Discovery, Inc.

Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Tatiana Shelekhin

David R Lancia, Jr

Gary Gustafson

Xiaozhang Zheng

Zhongguo Wang

David James Richard

Neal Green

Lorna Mitchell

Ann-Marie Campbell

Anna M Ericsson

Justin Andrew Caravella

David Joseph Guerin

Hongbin Li

Pui Yee Ng

Bingsong Han

Stephanos Ioannidis

Chase C Smith

Steven Gregory Mischke

Shawn E R Schiller

Stephen J O'Connor

Kenneth W Bair

Roger Astbury Smith

Jacques P Dumas

Wendy Lee

Derek B Lowe

Janet L Ralbovsky

Mary-Margaret Zablocki

Steven R Magnuson

Gaetan H Ladouceur

Uday R Khire

William H Bullock

Zhiyong Luo

Quanrong Shen

Ming Wang

Holia Hatoum-Mokdad

Jian Lin

Barton W Phillips

Gan Wang

Kyle E Parcella

Roger B Clark

Xin Ma

R Paul Beckett

Carla M Gauss

Richard Foster

Christelle Henault

Robert Dean Dally

Ning Qi

Qingjie Liu

Miao Dai

Jr Lancia David R

David Gunn

Mario Lobell

Robert Zhiyong Luo

Julie A Dixon

Christiana I Iwuagwu

Jennifer R Downing

Jennifer Burke

Philip Coish

Christiana Iwuagwu

David Richard

Shihong Ying

Furahi Achebe

Andrea McClure

Christiana Akuche

Mary-Margaret E Zablocki

David Cantin

Derek Lowe

Frederick Ehrgott

Jeffrey Stebbins

Steven Mischke

Anna Ericsson

David Lancia

David R Lancia Jr

Shawn ER Schiller

Jr David R Lancia

Julie Dixon

Justin A Caravella

Shawn Er Schiller

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments. The present disclosure provides compounds of Formula (I).

Inhibiting deubiquitinase USP25 and USP28

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

Carboxamides as ubiquitin-specific protease inhibitors

The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).

Activating pyruvate kinase R

The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.

Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators

Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

Treating sickle cell disease with a pyruvate kinase R activating compound

Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).

Compositions for activating pyruvate kinase

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R, R, R, R, R, R, R, X, and n are described herein. 

Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors

The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia. 

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: where R, R, R, R, R, R, R, R, X, m, and n are described herein.

Thienopyridine carboxamides as ubiquitin-specific protease inhibitors

Growing community of inventors

Ridgefield, CT, United States of America

Tatiana Shelekhin